Seer, Inc. SEER

Seer, Inc. and Nanyang Technological University will share early findings from the PRECISE-SG100K proteomics study at HUPO 2026. Led by PRECISE Chief Scientific Officer John Chambers, the project scales population-level molecular profiling to 10,000 participants in Singapore, integrating proteomics with genomic, clinical, and phenotypic data from a multi-ethnic population. The study uses Seer’s Proteograph Product Suite with LC-MS to interrogate the circulating proteome at peptide-level resolution, delivering deeper proteome coverage—roughly 7–10 times more depth than direct plasma analysis—so researchers can explore low-abundance proteins and potential biomarkers. The workflow emphasizes reproducibility across thousands of samples to distinguish biology from technical variability. Seer cites early proteogenomic and epidemiological signals and frames the work as a step toward broader biomarker discovery and precision medicine. Additional events include a Seer Breakfast Symposium at HUPO and a poster on population-scale proteomics. Demonstrates scalable, deep proteomics via Proteograph in a large, diverse cohort, boosting credibility and potential future biomarker-driven revenue for Seer.

Seer, Inc. announced that David Horn, President, Chief Financial Officer and Treasurer, will depart on October 1, 2026 to pursue a private-sector opportunity. Charles Endweiss, currently VP of Financial Planning & Analysis, will become Treasurer, principal financial officer and principal accounting officer on that date. CEO Omid Farokhzad praised Horn and endorsed Endweiss as a capable successor, while Horn expressed pride in Seer and confidence in the finance team. Endweiss has led FP&A since 2021 and previously held operations roles at Carbon; he holds a BA and MBA. Seer, a proteomics company, emphasizes Proteograph products for deep, unbiased proteomic insights. The release includes standard forward-looking statements and contact information for media and investors. Internal succession with a long-tenured finance leader suggests limited disruption and a balanced short-term impact on financial operations and investor sentiment.

Seer surpasses 100 peer-reviewed customer publications, validating deep proteomics at scale. Publication milestone strengthens proteomics credibility without major immediate financial or strategic shifts.

Seer (SEER) released its Q2 2026 earnings call transcript covering quarterly financial results and operational updates. Quarterly earnings data typically influences near-term stock sentiment without guaranteeing long-term trajectory shifts.

Radoff-JEC Group demands Seer, Inc.'s board publicly acknowledge the need to take the company private and disclose timelines for evaluating latest acquisition offers. Activist calls for privatization and acquisition reviews signal potential major strategic shifts affecting ownership structure and operations.

Seer, Inc. conducted its Q2 2026 earnings call covering financial results, operational updates and forward outlook. Quarterly earnings call supplies performance data and guidance that can shift near-term investor sentiment without guaranteeing major strategic change.

SEER reported Q2 2026 earnings amid funding headwinds, outlining steps to sustain operations and advance proteomics technology despite capital constraints. Funding headwinds signal moderate pressure on Seer Inc financial runway and growth plans.

Seer Inc. (SEER) Q2 earnings call highlights financial results, operational updates, and outlook for the period. Q2 earnings updates provide moderate insight into financial performance without signaling major strategic changes.

Seer reported second quarter 2026 financial results and reaffirmed its full year 2026 outlook. Quarterly results with reaffirmed outlook deliver moderate updates to financial trajectory and market views.

Seer confirms receipt of further revised unsolicited acquisition proposals from Radoff-JEC Group and from Omid Farokhzad, M.D. Unsolicited acquisition proposals signal potential ownership shifts and strategic changes for Seer.

Radoff-JEC Group submits further improved proposal to acquire Seer, Inc. Improved acquisition proposal targets Seer ownership change with major strategic implications.

Radoff-JEC Group announces Glass Lewis has joined ISS in supporting its campaign for changes at Seer, Inc. Proxy advisor endorsements for activists increase likelihood of board or strategic shifts affecting Seer governance and valuation.

Seer’s board special committee unanimously rejects Omid Farokhzad’s unsolicited acquisition proposal. Rejection of takeover bid may trigger brief share-price movement without altering operations or strategy.

Radoff-JEC Group announces ISS support for its campaign seeking changes at Seer, Inc. (SEER). ISS endorsement of activist demands raises prospects of governance or strategy shifts that can move Seer share price and direction.

Radoff-JEC Group issues letter to Seer, Inc. stockholders correcting company's rewriting of history. Activist letter signals governance dispute that can sway near-term investor sentiment.

Radoff-JEC Group responded to Seer Inc. Chairman and CEO Omid Farokhzad’s proposal to acquire the company. CEO acquisition proposal plus investor group response signals potential ownership change and strategic shift for Seer.

Seer shares surged 30% after release of an investor update ahead of the annual meeting. Positive investor update drove large short-term share price gain without evidence of fundamental long-term shifts.

Seer receives unsolicited acquisition proposal from Omid Farokhzad, M.D. Unsolicited acquisition proposal signals possible ownership change with major effects on strategy and valuation.

Seer prevails in European patent opposition. U.S. ITC opens investigation into Nanomics. Patent victory and ITC investigation may moderately affect Seer's IP position and competitive landscape.

The Radoff-JEC Group released a presentation urging Seer, Inc. stockholders to vote for boardroom changes at the company. Activist push for board changes at Seer may sway governance and short-term sentiment but outcome hinges on vote results.

The Radoff-JEC Group urges Seer, Inc. stockholders to vote for boardroom change today. Activist calls for board changes can influence governance and strategy but effects depend on vote outcome.

Seer and Korea University presented preliminary data at ASMS 2026 showing potential of AI-driven plasma proteomics for multi-cancer screening. Preliminary conference data on AI proteomics for cancer screening signals moderate innovation potential for Seer's core technology.

Radoff-JEC Group accuses Seer Inc. and CEO Omid Farokhzad of destroying shareholder value through past actions. Activist attacks on CEO track record can sway short-term investor sentiment and force strategic responses.

Seer board issues letter to shareholders highlighting scientific progress and rebutting Radoff and Torok activist campaign. Board letter may stabilize short-term sentiment without altering core operations or long-term trajectory.

Seer files ITC complaint against Nanomics. ITC complaint filing signals potential competitive legal action with moderate future impact.

Radoff-JEC Group urges Seer Inc. and its advisors to reassess premium acquisition proposal to serve all stockholders. Activist pressure on acquisition reevaluation may shift Seer Inc. strategy and short-term sentiment without guaranteed fundamental change.

Seer, Inc. (SEER) released Q1 2026 earnings call summary highlighting financial results, operational progress, key metrics, and forward guidance. Quarterly earnings summaries detail financial performance and guidance that significantly sway investor sentiment and stock trajectory.

The Radoff-JEC Group submitted its third non-binding proposal to acquire Seer, Inc. (SEER). Repeated non-binding acquisition proposals indicate strong buyer interest, potentially driving significant changes in company trajectory and stock performance.

Seer Inc (SEER) Q1 2026 earnings call reveals revenue decline amid intensifying competition, with management navigating challenges to future growth. Revenue decline and competitive pressures indicate major hurdles to Seer's financial performance and market trajectory.

Seer, Inc. (SEER) Q1 earnings call highlighted $4.1 million revenue, up 14% YoY; narrowed net loss to $36.9 million; $246 million cash runway into 2026; progress on Proteograph library yield improvements; reaffirmed 2024 revenue guidance of $22-26 million; emphasized commercial expansion and proteomics platform advancements. Q1 results show financial progress and operational updates with moderate influence on trajectory amid biotech challenges.